Hemoglobin Variants and Hemoglobinopathies

Hemoglobin Variants and Hemoglobinopathies - Oxygen's Ride & Its Woes

• Normal Hemoglobin (Hb): Structure & Adult Percentages
  • HbA ($\alpha_2\beta_2$): Predominant form, >95%.
  • HbA2 ($\alpha_2\delta_2$): Minor component, 1.5-3.5%.
  • HbF ($\alpha_2\gamma_2$): Fetal Hb, trace amounts <1-2% in adults.
• Hemoglobinopathies: Genetic Hb Disorders
  • Qualitative: Structural variants due to altered globin chain (e.g., HbS).
  • Quantitative (Thalassemias): Decreased synthesis of one or more globin chains.

⭐ Normal adult hemoglobin primarily consists of HbA ($\alpha_2\beta_2$), with small amounts of HbA2 ($\alpha_2\delta_2$) and HbF ($\alpha_2\gamma_2$).

, their globin chain compositions, and typical percentages)

Hemoglobin Variants and Hemoglobinopathies - Twisted Tales of Sickling

• Sickle Cell Disease (SCD):
  • Genetics: Autosomal recessive; β-globin gene mutation (GAG→GTG, $Glu \rightarrow Val$ at 6th position).
  • Pathophysiology: Under hypoxia, HbS polymerizes → RBCs sickle → vaso-occlusion, chronic hemolysis.

*   Clinical Features:
    *   Vaso-occlusive crisis (VOC): Severe pain. 📌 Factors: Dehydration, Infection, Hypoxia, Acidosis (DIHA).
    *   Acute Chest Syndrome (ACS): Fever, cough, chest pain, hypoxia.
    *   Aplastic crisis (e.g., Parvovirus B19).
    *   Splenic sequestration / Autosplenectomy: ↑ risk of infection by encapsulated organisms (e.g., S. pneumoniae).
*   Diagnosis: Sickling test (screening); Hb electrophoresis/HPLC (confirmatory: HbS predominant, no HbA in HbSS).
*   Management: Hydroxyurea (↑HbF), hydration, analgesia, blood transfusions.
    > ⭐ Hydroxyurea increases HbF production, which is a cornerstone in the management of Sickle Cell Disease.

• Other Hemoglobin Variants:
  • HbC Disease: $Glu \rightarrow Lys$ at β6. Mild chronic hemolytic anemia, splenomegaly, target cells.
  • HbE Trait/Disease: $Glu \rightarrow Lys$ at β26. Common in SE Asia. Mild microcytic anemia.

Hemoglobin Variants and Hemoglobinopathies - Chain Production Plight

• Thalassemias: Genetic disorders characterized by decreased synthesis of either α or β globin chains, leading to imbalanced globin chain production and defective hemoglobinization.
• Beta-Thalassemia (HBB gene mutations):
  • Minor (Trait): 1 gene defect; typically asymptomatic or mild microcytic hypochromic anemia; characteristic ↑HbA2 (>3.5%).
  • Intermedia: Variable clinical severity, bridging minor and major forms.
  • Major (Cooley's Anemia): 2 gene defects; severe, transfusion-dependent microcytic hypochromic anemia, hepatosplenomegaly, characteristic bone deformities (e.g., "crew-cut" skull, chipmunk facies due to extramedullary hematopoiesis); marked ↑HbF, ↑HbA2.
• Alpha-Thalassemia (HBA1/HBA2 gene deletions):
  • Silent Carrier: 1 gene deletion (-α/αα); clinically normal.
  • Trait: 2 gene deletions (--/αα or -α/-α); mild microcytic hypochromic anemia.
  • HbH Disease: 3 gene deletions (--/-α); excess β chains form β4 tetramers (HbH); moderate to severe chronic hemolytic anemia, splenomegaly.
  • Hydrops Fetalis (Hb Barts): 4 gene deletions (--/--); excess γ chains form γ4 tetramers (Hb Barts); severe intrauterine anoxia, lethal in utero or postnatally.
• Diagnosis: CBC (microcytic hypochromic anemia), peripheral smear (target cells, poikilocytosis, basophilic stippling), Hb electrophoresis/HPLC for quantitative Hb analysis (HbA2, HbF).

⭐ Beta-thalassemia major presents with severe microcytic hypochromic anemia and characteristically elevated HbF and HbA2 levels.

Hemoglobin Variants and Hemoglobinopathies - Lab Sleuths & Blue Bloods

• Diagnostics: CBC, smear (RBC indices/morphology); Hb electrophoresis (cellulose acetate pH 8.6, citrate agar pH 6.2); HPLC (quantitative); DNA analysis (mutations/deletions).
• Methemoglobinemia:
  • Iron in heme oxidized: $Hb(Fe^{2+}) \rightarrow MetHb(Fe^{3+})$; cannot bind $O_2$.
  • Causes: Oxidant drugs (dapsone, nitrites), enzyme deficiencies (cytochrome b5 reductase).
  • Clinical: Cyanosis, chocolate-brown blood.
  • Diagnosis: Co-oximetry (metHb levels >1%).
  • Treatment: Methylene blue (if G6PD normal), ascorbic acid.

⭐ Methylene blue is the antidote for symptomatic methemoglobinemia, acting as an electron acceptor for NADPH methemoglobin reductase.

High‑Yield Points - ⚡ Biggest Takeaways

• Sickle Cell (HbS): β-globin Glu6Val mutation; vaso-occlusion, hemolysis, sickling.
• β-Thalassemia: Deficient β-globin synthesis; Major causes severe transfusion-dependent anemia.
• α-Thalassemia: Deficient α-globin synthesis from gene deletions; Hb Bart's (γ₄) is key.
• HbC Disease: β-globin Glu6Lys mutation; mild hemolysis, hexagonal/rod-shaped crystals.
• HbE Disease: β-globin Glu26Lys mutation; common in SE Asia, mild microcytic anemia.
• Methemoglobinemia: Oxidized Fe³⁺ heme (cannot bind O₂); cyanosis, treat with methylene blue.
• Diagnosis: HPLC & Hb electrophoresis are crucial for identifying variants.